Is Rapid Cost-cutting The Answer To Merck’s R&D Woes?
This article was originally published in The Pink Sheet Daily
Executive Summary
The Big Pharma has had plenty of problems with its pipeline in recent years but has taken steps to move the needle back in the right direction. For some analysts and investors that progress is not coming rapidly enough.